Pathophysiology of vitiligo

Clinics in Dermatology

Volumn 15, Issue 6, 1997, Pages 845-851

  Castanet, Jerome ^a   Ortonne, Jean Paul ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AUTOANTIBODY; CATECHOLAMINE; DNA; FREE RADICAL; MELANIN; MONOCLONAL ANTIBODY; MONOPHENOL MONOOXYGENASE; NEUROTRANSMITTER; PHENYLALANINE; TETRAHYDROBIOPTERIN; TYROSINE; VIRUS DNA;

AUTOIMMUNITY; CATECHOLAMINE SYNTHESIS; CELLULAR IMMUNITY; CHICKEN; CYTOMEGALOVIRUS; ETIOLOGY; FAMILY HISTORY; HEREDITY; HUMAN; LANGERHANS CELL; MELANOCYTE; MELANOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS INFECTION; VITILIGO;

EID: 0030728588     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00125-9     Document Type: Article

References (64)

1. Ortonne JP, Bose SK. Vitiligo. Where do we stand? Pigment Cell Res 1993;6:61-72.
2. Le Poole 1C, Das PK, van den Wijngaard RMJGJ, et al. Review of the etiopathomechanism of vitiligo: A convergence theory. Exp Dermatol 1993;2:145-53.
3. Bystryn JC. Serum antibodies in vitiligo patients. Clin Dermatol 1989;2:136-45.
4. Le Poole 1C, van den Wijngaard RMJGJ, Westerhof W, et al. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol 1993;100:816-22.
5. Bhawan J, Bhutani LK. Keratinocyte damage in vitiligo. J Cutan Pathol 1983;10:207-12.
6. Ishii M, Hamada T. Ultrastructural studies of vitiligo with inflammatory raised borders. J Dermatol 1981;8:313-22.
7. Moeilmann G, Klein-Angerer S, Scolly DA, et al. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol 1982;79:321-30.
8. Breathnach AS, Bor S, Wyllie LMA. Electron microscopy of peripheral nerve terminals and marginal melanocytes in vitiligo. J Invest Dermatol 1966;47:125-40.
9. Harm SK, Park YK, Lee KG, et al. Epidermal changes in active vitiligo. J Dermatol 1992;19:217-22.
10. Austin LM, Boissy RE. Mammalian tyrosinase-relatred protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. Am J Pathol 1995;146:1529-41.
11. Lament SJ, Smyth JR Jr. Effect of bursectomy on develop-ment of a spontaneous postnatal amelanosis. Clin Immunol Pathol 1981;21:407-11.
12. Boissy RA, Moellmann GE, Trainer AT, et al. Delayed amelanotic (DAM or Smyth) chicken: Melanocyte dysfunction in vivo and in vitro. J Invest Dermatol 1986;86: 149-56.
13. Smyth JR Jr. The Smyth chicken: A model of autoimmune amelanosis. Curr Rev Poult Biol 1989;2:1-19.
14. Lerner AB, Shiohara T, Boissy RE, et al. A mouse model for vitiligo. J Invest Dermatol 1986;87:299-304.
15. Smith SB, Cope BK, McCoy JR, et al. Reduction of phagosomes in the vitiligo (C57BL/6-miVIt/miVIt) mouse model of retinal degeneration. Invest Ophtalmol Vis Sei 1994;35: 3625-32.
16. Smith SB, Duncan T, Kutty G, et al. Increase in retinyl palmitate concentration in eyes and livers and the concentration of interphotoreceptor retinoid-binding protein in eyes of vitiligo mutant mice. Biochem J 1994;300:63-8.
17. Nordlund JJ, Csato M, Babcock G, et al. Low ICAM-1 expression in the epidermis of depigmenting C57BL/6Jmivit/mivit mice: A possible cause of muted contact sensitization. Exp Dermatol 1995;4:20-9.
18. Bowers RB, Lujan J, Biboso A, et al. Premature avian melanocyte death due to low antioxidant levels of protection: Fowl model for vitiligo. Pigment Cell Res 1994;7: 409-18.
19. Jackson IJ, Budd P, Horn JM, et al. Genetics and molecular biology of mouse pigmentation. Pigment Cell Res 1994;7: 73-80.
20. Kamada S, Shimono A, Shinto Y, et al. Bcl-2 deficiency in mice leads to pleiorropic abnormalities: Accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res 1995;55:354-59.
21. Veis DJ, Sorenson CM, Schutter JR, et al. Bcl-2 deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidney, and hypopigmented hair. Cell 1993;75:22940.
22. Nakayama K, Nakayama KI, Neghishi I, et al. Targeted distribution of bcl-2αβ in mice: Occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sei USA 1994;91:3700-4.
23. Yamamura K, Kamada S, Ito S, et al. Accelerated disappearance of melanocytes in bd-2 deficient mice. Cancer Res 1996;56:3546-50.
24. Naughton GK, Eising M, Bystryn JC. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983;81:540-42.
25. Norris DA, Kissinger RM, Naughton GK, et al. Evidence for immunologie mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody dependent cellular cytotoxicity (ADCC). J Invest Dermatol 1988;90: 783-9.
26. Yu CL, Kao CH, Yu HS. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental type vitiligo. J Invest Dermatol 1993;100:823-8.
27. Cui J, Harning R, Henn M, et al. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992;98:162-5.
28. Cui I, Arita J, Bystryn JC. Characterization of vitiligo antigens. Pigment Cell Res 1995;8:53-9.
29. Song YH, Connor E, Li Y, et al. The role of tyrosine in autoimmune vitiligo. Lancet 1994;344:1049-52.
30. Naughton GK, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986;15:978-81.
31. Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991;97:1078-80.
32. Cui I, Arita J, Bystryn JC. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993;100:812-5.
33. Norris DA, Capin L, Muglia JJ, et al. Enhanced suceptibility of melanocytes to different immunologie effector mechanisms in vitro: Potential mechanisms for postinflammatory hypopigmentation and vitiligo. Pigment Cell Res 1988;l"(Suppl l):113-23.
34. Take M, Mishima Y, Uda H. Immunopathology of vitiligo vulgaris, Button's leukoderma and melanoma-associated vitiligo in relation to steroid effects. II. IgG and C3 deposits in skin. J Cut Pathol 1984;ll:114-24.
35. Gilhar A, Pillar T, David M, et al. Melanocytes and Langerhans cells in aged versus young skin before and after transplantation onto nude mice. J Invest Dermatol 1991; 96:210-4.
36. Gilhar A, Zelickson B, Ulman Y, et al. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995;105:683-6.
37. Ho RC. Medical management of stage IV malignant melanoma. Medical issues. Cancer 1995;75 (Suppl 2):735-41.
38. Scheibenbogen C, Hunstein W, Keilholz U. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer 1994;30A:1209-10.
39. Wolkenstein P, Revuz J, Guillaume JC, et al. Autoimmune disorders and interleukin-2 therapy: A step toward unanswered questions. Arch Dermatol (letter comment) 1995; 131:615-6.
40. Cui J, Bystryn JC. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 1995;131:314-8.
41. Durham-Pierre DG, Walters CS, Halder RM, et al. Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo. J Am Acad Dermatol 1995; 33:26-30.
42. Goudie RB. Two views of the origin of vitiligo. Lancet 1991;338:316-8.
43. Le Poole, Van den Wijngaard RM, Westerhf W, et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 19%;148:1219-28.
44. AI Badri AMT, Foulis AK, Todd P, et al. Abnormal expression of MHC class II and Icam-1 by melanocytes in vitiligo. J Pathol 1993; 169:203-6.
45. Abdel-Naser MB, Ludwig WD, Gollnick H, et al. Non segmental vitiligo: Decrease of the CD 45 RA+ T-cell subset and evidence for peripheral T-cell activation. Int J Dermatol W2;35:321-6.
46. Hatchrome N, Aiba S, Kato T, et al. Possible functional impairment of Langerhans' cells in vitiliginous skin. Arch Dermatol 1987;123:51-4.
47. AI Badri AMT, Todd PM, Garioch J, et al. An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 1993;170.149-55.
48. Lacour JP, Ortonne IP. Génétique du vitiligo. Ann Dermatol Vénéréol 1995;122:167-71.
49. Narth SK, Majumder PP, Nordlund JJ.enetic epidemiology of vitiligo: Multilocus recessivifs cross-validated. Am J Hum Genet 1994;55:981-90.
50. Boissy RA, Liu YY, Medrano EE, et al. Structural aberration of the rough endoplasmic reticulum and melanosorne compartmentalization in long-term cultured melanocytes from vitiligo patients. J Invest Dermatol ]991;97:395-404.
51. Im S, Hann SK. Biologic characteristics ot cultured human vitiligo melanocytes. Int J Dermatol 1994;33:556-62.
52. Finco O, Cuccia M, Martinetti M, et al Age of onset in vitiligo: relationship with H LA supra types. Clinical Genetics 1991;39:48-54.
53. Horikawa T, Norris DA, Yohn j, et al. Vtelanocyte mitogens induce both melanocyte chemokinesis and chemotaxis. J Invest Dermatol 1995:104:256-9
54. Norris A, Todd C, Graham A, et al The expression of the c-kit receptor by epidermal melanocytes may be reduced in vitiligo. Br J Dermatol 1996; 134:299-306
55. Cosulich S, Clarke P. Apoptosis: Does stress kill? Curr Biol 1996:6:1586-7.
56. Plettenberg A, Ballaun C, Pammer |, et al. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene hi situ and in O'll culture. Am J Pathol 1995:146:651-9.
57. Westerhof W. Vitiligo-A window in the darkness. Dermatology 1995;190:181-2.
58. Al'Abadie MS, Warren MA, Blechen SS. et al. Morphologie observations on the dermal nerves in vitiligo: An ultrastructural study. Int J Dermatol 1995:34:837-40.
59. Hara M, Toyoda M, Yaar M, et al. Innervation of melanocytes in human skin. J Exp Med 1996:1 4:1385- 95.
60. Mozzanica N, Villa ML, Foppa S, et al. Plasma α-melanocyte stimulating-hormone, β endorphin, met-enkephalin, and natural killer cell activity in vitiligo, j Am Acad Dermatol 1992:26:693-700.
61. Al'Abadie MSK, Gawkrodger HJ, Warren MA, et al. Neuro-ultrastructural and neuropeptide sudies in vitiligo (abstract). Clin Exp Dermatol 1992;15'2M4.
62. Grimes PE, Sevall |S, Vodjani A. Cvtomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo. J Am Acad Dermatol 1996:35:21
63. Norris DA, Horikawa, Morelli JG. Melaaocyte destruction and repopulation in vitiligo. Pigment GH Res 1994:7:193203.
64. Grichnik JM, Ali VVN, Burch JA, et J. KIT expression reveals a population of precursor mt'l.mocvtes in human skin. I Invest Dermatol 1996;l()6:967-7.